Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus filovirus immunogen including a consensus Marburgvirus filovirus glycoprotein MARV GP immunogen, a consensus Ebolavirus Sudan filovirus glycoprotein SEBOV GP immunogen and a consensus Ebolavirus Zaire glycoprotein ZEBOV GP immunogen are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against filovirus, particularly Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Method of preventing filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire and methods of treating individuals infected with filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Consensus filovirus proteins are disclosed.
1. A composition comprising one or more nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
a) a nucleic acid sequence that encodes a first consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the first consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:4 (MARV CON1), a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:4, SEQ ID NO:4 (MARV CON1) linked to an IgE signal peptide, and a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:4 linked to an IgE signal peptide;
b) a nucleic acid sequence that encodes a second consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the second consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:5 (MARV CON2), a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:5, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:5, a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:5 over 600 or more consecutive amino acids, SEQ ID NO:5 (MARV CON2) linked to an IgE signal peptide, a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 600 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:5 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:5 that comprises 600 or more consecutive amino acids of SEQ ID NO:5 linked to an IgE signal peptide; and
c) a nucleic acid sequence that encodes a second consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the second consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:6 (MARV CON3), a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:6, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:6, a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:6 over 600 or more consecutive amino acids, SEQ ID NO:6 (MARV CON3) linked to an IgE signal peptide, a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 600 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:6 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:6 that comprises 600 or more consecutive amino acids of SEQ ID NO:6 linked to an IgE signal peptide.
2. The composition of claim 1 comprising: a first plasmid that comprises a nucleic acid sequence that encodes the first consensus Marburg marburgvirus envelope glycoprotein immunogen; a second plasmid that comprises a nucleic acid sequence that encodes the second consensus Marburg marburgvirus envelope glycoprotein immunogen; and a third plasmid that comprises a nucleic acid sequence that encodes the third consensus Marburg marburgvirus envelope glycoprotein immunogen.
3. The composition of claim 1 wherein:
a) the amino acid sequence of the first consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:4 (MARV CON1), a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 630 or more consecutive amino acids of SEQ ID NO:4, SEQ ID NO:4 (MARV CON1) linked to an IgE signal peptide, and a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 630 or more consecutive amino acids of SEQ ID NO:4 linked to an IgE signal peptide;
b) the amino acid sequence of the second consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:5 (MARV CON2), a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 630 or more consecutive amino acids of SEQ ID NO:5, an amino acid sequence that is at least 98% identical to the full length of SEQ ID NO:5, a fragment of an amino acid sequence that is at least 98% identical to SEQ ID NO:5 over 630 or more consecutive amino acids, SEQ ID NO:5 (MARV CON2) linked to an IgE signal peptide, a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 630 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 98% identical to the full length of SEQ ID NO:5 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 98% identical to SEQ ID NO:5 that comprises 630 or more consecutive amino acids of SEQ ID NO:5 linked to an IgE signal peptide; and
c) the amino acid sequence of the third consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:6 (MARV CON3), a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 630 or more consecutive amino acids of SEQ ID NO:6, an amino acid sequence that is at least 98% identical to the full length of SEQ ID NO:6, a fragment of an amino acid sequence that is at least 98% identical to SEQ ID NO:6 over 630 or more consecutive amino acids, SEQ ID NO:6 (MARV CON3) linked to an IgE signal peptide, a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 630 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 98% identical to the full length of SEQ ID NO:6 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 98% identical to SEQ ID NO:6 that comprises 630 or more consecutive amino acids of SEQ ID NO:6 linked to an IgE signal peptide.
4. The composition of claim 3 comprising: a first plasmid that comprises a nucleic acid sequence that encodes the first consensus Marburg marburgvirus envelope glycoprotein immunogen; a second plasmid that comprises a nucleic acid sequence that encodes the second consensus Marburg marburgvirus envelope glycoprotein immunogen; and a third plasmid that comprises a nucleic acid sequence that encodes the third consensus Marburg marburgvirus envelope glycoprotein immunogen.
5. The composition of claim 3 wherein:
a) the amino acid sequence of the first consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:4 (MARV CON1), a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 660 or more consecutive amino acids of SEQ ID NO:4, SEQ ID NO:4 (MARV CON1) linked to an IgE signal peptide, and a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 660 or more consecutive amino acids of SEQ ID NO:4 linked to an IgE signal peptide;
b) the amino acid sequence of the second consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:5 (MARV CON2), a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 660 or more consecutive amino acids of SEQ ID NO:5, an amino acid sequence that is at least 99% identical to the full length of SEQ ID NO:5, a fragment of an amino acid sequence that is at least 99% identical to SEQ ID NO:5 over 660 or more consecutive amino acids, SEQ ID NO:5 (MARV CON2) linked to an IgE signal peptide, a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 660 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 99% identical to the full length of SEQ ID NO:5 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 99% identical to SEQ ID NO:5 that comprises 660 or more consecutive amino acids of SEQ ID NO:5 linked to an IgE signal peptide; and
c) the amino acid sequence of the third consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:6 (MARV CON3), a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 660 or more consecutive amino acids of SEQ ID NO:6, an amino acid sequence that is at least 99% identical to the full length of SEQ ID NO:6, a fragment of an amino acid sequence that is at least 99% identical to SEQ ID NO:6 over 660 or more consecutive amino acids, SEQ ID NO:6 (MARV CON3) linked to an IgE signal peptide, a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 660 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 99% identical to the full length of SEQ ID NO:6 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 99% identical to SEQ ID NO:6 that comprises 660 or more consecutive amino acids of SEQ ID NO:6 linked to an IgE signal peptide.
6. The composition of claim 5 comprising: a first plasmid that comprises a nucleic acid sequence that encodes the first consensus Marburg marburgvirus envelope glycoprotein immunogen; a second plasmid that comprises a nucleic acid sequence that encodes the second consensus Marburg marburgvirus envelope glycoprotein immunogen; and a third plasmid that comprises a nucleic acid sequence that encodes the third consensus Marburg marburgvirus envelope glycoprotein immunogen.
7. The composition of claim 5 wherein: the first consensus Marburg marburgvirus envelope glycoprotein immunogen has an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:4 linked to an IgE signal peptide; the second consensus Marburg marburgvirus envelope glycoprotein immunogen has an amino acid sequence selected from the group consisting of SEQ ID NO:5 and SEQ ID NO:5 linked to an IgE signal peptide; and the third consensus Marburg marburgvirus envelope glycoprotein immunogen has an amino acid sequence selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:6 linked to an IgE signal peptide.
8. The composition of claim 7 comprising: a first plasmid that comprises a nucleic acid sequence that encodes SEQ ID NO:4 or SEQ ID NO:4 linked to an IgE signal peptide; a second plasmid that comprises a nucleic acid sequence that encodes of SEQ ID NO:5 or SEQ ID NO:5 linked to an IgE signal peptide; and a third plasmid that comprises a nucleic acid sequence that encodes SEQ ID NO:6 or SEQ ID NO:6 linked to an IgE signal peptide.
9. The composition of claim 1 formulated for delivery to an individual using electroporation.
10. The composition of claim 1 further comprising nucleic acid sequences that encode one or more proteins selected from the group consisting of: IL-12, IL-15 and IL-28.
11. A composition comprising two or more proteins selected from the group consisting of:
a first consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the first consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:4 (MARV CON1), a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:4, SEQ ID NO:4 (MARV CON1) linked to an IgE signal peptide, and a fragment of SEQ ID NO:4 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:4 linked to an IgE signal peptide;
a second consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the second consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:5 (MARV CON2), a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:5, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:5, a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:5 over 600 or more consecutive amino acids, SEQ ID NO:5 (MARV CON2) linked to an IgE signal peptide, a fragment of SEQ ID NO:5 that comprises a sequence having 100% identity over 600 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:5 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 95% to SEQ ID NO:5 that comprises 600 or more consecutive amino acids of SEQ ID NO:5 linked to an IgE signal peptide; and
a third consensus Marburg marburgvirus envelope glycoprotein immunogen, wherein the amino acid sequence of the second consensus Marburg marburgvirus envelope glycoprotein immunogen is selected from the group consisting of: SEQ ID NO:6 (MARV CON3), a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 600 or more consecutive amino acids of SEQ ID NO:6, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:6, a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:6 over 600 or more consecutive amino acids, SEQ ID NO:6 (MARV CON3) linked to an IgE signal peptide, a fragment of SEQ ID NO:6 that comprises a sequence having 100% identity over 600 or more consecutive amino acids linked to an IgE signal peptide, an amino acid sequence that is at least 95% identical to the full length of SEQ ID NO:6 linked to an IgE signal peptide, and a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:6 that comprises 600 or more consecutive amino acids of SEQ ID NO:6 linked to an IgE signal peptide.